secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K
Filed at:   2026-05-11T20:33:41+00:00
Accession:  0001193125-26-216929
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst Q1 2026 revenue $149.4M; FIRDAPSE up 18%, AGAMREE up 67% YoY
---------------------------------------------------------------------

- Product revenue net $149.3M for Q1 2026, up 5.6% YoY from $141.4M.
- FIRDAPSE net revenue $98.9M (+18% YoY); AGAMREE $36.7M (+67%); FYCOMPA $13.8M (-61%).
- GAAP net income $63.7M ($0.52 basic EPS); non-GAAP net income $100.3M ($0.82 basic EPS).
- Cash & equivalents $755.9M at March 31, 2026, up from $709.2M; no funded debt.
- No forward guidance or updated FY2026 outlook provided in the release.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312526216929/0001193125-26-216929-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312526216929/d845745d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-216929

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer